AstraZeneca plc 8.3% Potential Upside Indicated by Kepler Cheuvreux

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Kepler Cheuvreux. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set their target price at 8000 GBX on its stock. This now indicates the analyst believes there is a possible upside of 8.3% from the opening price of 7386 GBX. Over the last 30 and 90 trading days the company share price has increased 125 points and increased 273 points respectively. The 52 week high for the share price is currently at 7622 GBX while the 52 week low for the share price is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 7,212.15 GBX and a 200 Day Moving Average share price is recorded at 6,505.37. There are currently 1,311,894,438 shares in issue with the average daily volume traded being 2,363,353. Market capitalisation for LON:AZN is £96,437,360,137 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

      Search

      Search